ThromboGenics
31
0
0
25
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
High Risk
Score: 75/100
16.1%
5 terminated/withdrawn out of 31 trials
83.3%
-3.2% vs industry average
10%
3 trials in Phase 3/4
40%
10 of 25 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (31)
Treatment of Post-Ocriplasmin Therapy Vitreolysis Induced Subretinal Fluid With Eplerenone (Mineralocorticoid Antagonists)
Role: collaborator
A Study to Evaluate the Efficacy and Safety of Ocriplasmin in Inducing Total PVD in Subjects With NPDR
Role: lead
A Study to Evaluate THR-317 Treatment for Macular Telangiectasia Type 1 (MacTel 1)
Role: lead
A Study to Evaluate the Safety of THR-687 in Subjects With Diabetic Macular Edema (DME)
Role: lead
A Study to Evaluate the Safety of THR-149 in Subjects With Diabetic Macular Edema (DME)
Role: lead
A Study to Evaluate the Safety and Efficacy of THR-317 for the Treatment of Diabetic Macular Oedema (DME)
Role: lead
Prevalence of Vitreomacular Adhesion in Patients 40 Years and Older
Role: collaborator
Follow-up Study to Assess Visual Function in Subset of Patients Who Have Previously Participated in the TG-MV-006 and TG-MV-007 Ocriplasmin Studies
Role: lead
Ocriplasmin Research to Better Inform Treatment (ORBIT)
Role: lead
Ocriplasmin for Treatment for Symptomatic Vitreomacular Adhesion Including Macular Hole
Role: lead
A Retrospective Chart Review of Patients Treated With Ocriplasmin for Symptomatic VMA
Role: lead
A Study to Compare Multiple Doses Intravitreal Microplasmin for Treatment of Patients With Vitreomacular Traction (MIVI-IIt)
Role: lead
Trial of Microplasmin Intravitreal Injection for Non-surgical Treatment of Focal Vitreomacular Adhesion. The MIVI-TRUST (TG-MV-006) Trial.
Role: lead
Clinical Trial of Intravitreal Microplasmin in Infants and Children Scheduled for Vitrectomy
Role: lead
Safety and Efficacy Study of Intravitreal Ocriplasmin in Subjects With AMD With Focal Vitreomacular Adhesion
Role: lead
The Purpose of This Study is to Evaluate the Pharmacokinetic Properties of Intravitreal Ocriplasmin Prior to Planned Primary Pars Plana Vitrectomy (PPV)
Role: lead
Trial of Microplasmin Intravitreal Injection for Non-Surgical Treatment of Focal Vitreomacular Adhesion. The MIVI-TRUST (TG-MV-007) Trial.
Role: lead
A Study of the Safety and Efficacy of Microplasmin to Induce a Posterior Vitreous Detachment (MIVI III)
Role: lead
A Multicenter Study to Compare Multiple Doses of Intravitreal Microplasmin Versus Sham Injection for Treatment of Patients With Diabetic Macular Edema (DME)
Role: lead
Intravenous Administration of Microplasmin for Treatment of Acute Ischemic Stroke
Role: lead